Treatment, overall survival, and costs in patients withALK-positive non-small-cell lung cancer after crizotinib monotherapy
| Autor: | Roy Nitulescu, Medha Sasane, Jie Zhang, Katherine Dea, Philip Galebach, Alexander R. Macalalad, Heather A. Wakelee, Kenneth W. Culver, Annie Guerin |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms Pyridines Crizotinib Carcinoma Non-Small-Cell Lung Internal medicine medicine Overall survival Humans Anaplastic lymphoma kinase Anaplastic Lymphoma Kinase Intensive care medicine Lung cancer Protein Kinase Inhibitors Aged Ceritinib Brain Neoplasms business.industry Medical record ALK-Positive Receptor Protein-Tyrosine Kinases Health Care Costs General Medicine Middle Aged medicine.disease Pyrazoles Female Non small cell business medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 31:1587-1597 |
| ISSN: | 1473-4877 0300-7995 |
| Popis: | Limited post-crizotinib treatment options for ALK-positive non-small cell lung cancer (NSCLC) might lead to poor survival and high economic burden.To evaluate real-world treatment patterns, overall survival (OS), and costs following crizotinib discontinuation.This study used chart review and claims data. First, 27 participating US oncologists reviewed medical records of ALK-positive NSCLC patients who discontinued crizotinib monotherapy and reported patient demographic and clinical information, including post-crizotinib treatment and mortality. OS was estimated using Kaplan-Meier analyses. Second, three large administrative US claims databases were pooled. NSCLC patients were selected if they discontinued crizotinib monotherapy. Post-crizotinib costs were analyzed separately for patients who did or did not discontinue antineoplastic treatment after crizotinib monotherapy. All data were collected prior to ceritinib approval for this patient population.A total of 119 ALK-positive NSCLC patients discontinued crizotinib monotherapy. Upon discontinuation, 42% had no additional antineoplastic treatment and 13% received radiation therapy only. The median OS post-crizotinib was 61 days; patients with brain metastases had shorter OS than those who did not (44 vs. 69 days, P = 0.018), and patients without further antineoplastic treatment had shorter OS than those who did (17 vs. 180 days, P 0.001). From claims data, 305 ALK-positive NSCLC patients discontinued crizotinib monotherapy. After discontinuation, 72% had no additional antineoplastic treatment. Among patients who continued antineoplastic treatment, monthly healthcare costs averaged $22,160, driven by pharmacy ($9202), inpatient ($6419), and outpatient radiotherapy ($2888) and imaging ($1179) costs. Among patients who discontinued any antineoplastic treatment, monthly healthcare costs averaged $3423, mostly driven by inpatient costs ($2074).After crizotinib monotherapy, most patients either received radiotherapy only or discontinued antineoplastic treatment altogether. OS after discontinuing crizotinib was poor and shorter among those with brain metastases than without, and among those without subsequent antineoplastic treatment than with. Patients who continued antineoplastic treatment incurred substantial healthcare costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|